Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 578Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersRenal cell carcinoma treatment

The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Abstract

BACKGROUND Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through multiple mechanisms and augmented antitumour activity in multiple malignancies. We aimed to assess the efficacy and safety of atezolizumab (anti-PD-L1) alone and combined with bevacizumab (anti-VEGF) in patients with unresectable hepatocellular carcinoma. METHODS GO30140 is an open-label, multicentre, multiarm, phase 1b study that enrolled patients at 26 academic centres and community oncology practices in seven countries worldwide. The study included five cohorts, and the two hepatocellular carcinoma cohorts, groups A and F, are described here. Inclusion criteria for these two groups included age 18 years and older; histologically, cytologically, or clinically (per American Association for the Study of Liver Diseases criteria) confirmed unresectable hepatocellular carcinoma that was not amenable to curative treatment; no previous systemic treatment; and Eastern Cooperative Oncology Group performance status of 0 or 1. In group A, all patients received atezolizumab (1200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks. In group F, patients were randomly assigned (1:1) to receive intravenous atezolizumab (1200 mg) plus intravenous bevacizumab (15 mg/kg) every 3 weeks or atezolizumab alone by interactive voice-web response system using permuted block randomisation (block size of two) and stratification factors of geographical region; macrovascular invasion, extrahepatic spread, or both…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30156-x

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 578

Metadata

Authors
Lee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., Wang, Y., He, A. R., Lee, K.-H., Bang, Y.-J., Bendell, J., Chao, Y., Chen, J.-S., Chung, H. C., Davis, S. L., Dev, A., Gane, E., George, B., He, A. R., Hochster, H., Hsu, C.-H., Ikeda, M., Lee, J., Lee, M., Mahipal, A., Manji, G., Morimoto, M., Numata, K., Pishvaian, M., Qin, S., Ryan, D., Ryoo, B.-Y., Sasahira, N., Stein, S., Strickler, J., & Tebbutt, N.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Asan Medical Center (KR)
  • National Taiwan University Hospital (TW)
  • Genentech (US)
  • Seoul National University (KR)
Corresponding author
Lee, Kyung-Hun
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-06
Volume
21
Issue
6
Pages
808-820
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3033218405
Cited by
562
References
38
Citations by year
2026: 34 · 2025: 60 · 2024: 98 · 2023: 101 · 2022: 126 · 2021: 115 · 2020: 27
FWCI
54.25
Type
journal article
Language
en
Update notices
erratum (2020-07-01)
Open access
closed
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
F. Hoffmann-La Roche
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords
bevacizumab, hepatocellular carcinoma, unresectable liver cancer, PD-L1 blockade, VEGF inhibition, combination immunotherapy, objective response rate, progression-free survival, immune-related adverse events, alpha-fetoprotein, macrovascular invasion, extrahepatic spread, treatment efficacy and safety
MeSH terms
Bevacizumab, Antineoplastic Agents, Immunological, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neovascularization, Pathologic, Time Factors, Signal Transduction, Disease Progression, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30156-x
The paper
Lee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., Wang, Y., He, A. R., Lee, K.-H., Bang, Y.-J., Bendell, J., Chao, Y., Chen, J.-S., Chung, H. C., Davis, S. L., . . . Tebbutt, N. (2020). Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30156-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.